Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
| Current Price | ₹680.20 |
|---|---|
| Market Cap | ₹11,199 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Domestic contract manufacturers |
| P/E Ratio | 42.5 |
| Return on Equity | 8.02% |
| 52-Week Range | ₹409.30 – ₹838.80 |
| Beta (1Y) | 0.27 |
| Dividend Yield | 0.14% |
| Revenue | ₹1,167 Cr |
|---|---|
| Net Profit | ₹101 Cr |
| EPS (Basic) | ₹6.53 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. CDMO-85.1% 2. API-5.3% 3. Domestic Branded Formulations-10.2% 4. International Branded Formulations-3.3% 6. Trade Generics-2.3%
Akums Drugs and Pharmaceuticals Limited is trading at ₹680.20, with a market capitalisation of ₹11,199 Cr.
Akums Drugs and Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).
Akums Drugs and Pharmaceuticals Limited has a P/E of 42.5 and a return on equity of 8.02%.
In Q1 FY27, Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,167 Cr and net profit of ₹101 Cr, with basic EPS of ₹6.53 (consolidated, parsed from the company's exchange filing).